冠昊生物
(300238)
| 流通市值：30.68亿 | | | 总市值：30.68亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 174,516,375.45 | 93,444,027.57 | 387,749,767.9 | 293,480,433.06 |
| 营业总成本 | 161,974,132.06 | 83,859,027.31 | 358,622,829.07 | 261,309,394.44 |
| 其他经营收益 | | | | |
| 营业利润 | 13,140,180.72 | 10,701,296.25 | 30,453,513.15 | 31,441,561.02 |
| 利润总额 | 13,745,891.51 | 10,513,667.65 | 27,280,561.83 | 32,119,529.52 |
| 净利润 | 7,653,728.99 | 7,202,467.67 | 14,787,270.04 | 20,429,167.53 |
| 每股收益 | | | | |
| 其他综合收益 | -191,767.96 | -112,033.94 | -125,555.44 | -69,791.15 |
| 综合收益总额 | 7,461,961.03 | 7,090,433.73 | 14,661,714.6 | 20,359,376.38 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 297,314,828.49 | 307,842,566.62 | 325,608,234.99 | 300,732,354.2 |
| 非流动资产: | | | | |
| 非流动资产合计 | 482,070,808.89 | 479,380,405.23 | 480,924,177.2 | 473,774,578.98 |
| 资产总计 | 779,385,637.38 | 787,222,971.85 | 806,532,412.19 | 774,506,933.18 |
| 流动负债: | | | | |
| 流动负债合计 | 144,569,947.34 | 153,599,890.85 | 188,540,549.12 | 152,297,698.75 |
| 非流动负债: | | | | |
| 非流动负债合计 | 139,536,802.48 | 138,715,720.74 | 130,174,936.54 | 128,716,346.25 |
| 负债合计 | 284,106,749.82 | 292,315,611.59 | 318,715,485.66 | 281,014,045 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 583,115,533.9 | 580,117,758.49 | 570,067,516.98 | 572,121,327.51 |
| 股东权益合计 | 495,278,887.56 | 494,907,360.26 | 487,816,926.53 | 493,492,888.18 |
| 负债和股东权益合计 | 779,385,637.38 | 787,222,971.85 | 806,532,412.19 | 774,506,933.18 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 192,065,106.35 | 104,154,662.17 | 456,130,353.59 | 337,580,752.35 |
| 经营活动现金流出小计 | 198,836,210.23 | 117,978,802.31 | 384,656,557.83 | 284,944,912.18 |
| 经营活动产生的现金流量净额 | -6,771,103.88 | -13,824,140.14 | 71,473,795.76 | 52,635,840.17 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,580,122.15 | 1,579,662.15 | 3,177,691.34 | 27,914.35 |
| 投资活动现金流出小计 | 16,724,377.98 | 11,898,993.69 | 39,368,477.33 | 30,788,916.93 |
| 投资活动产生的现金流量净额 | -15,144,255.83 | -10,319,331.54 | -36,190,785.99 | -30,761,002.58 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 13,219,958.77 | 11,269,958.77 | 51,114,800 | 42,051,300 |
| 筹资活动现金流出小计 | 5,788,219.95 | 3,265,789.99 | 30,096,410.44 | 26,871,520.76 |
| 筹资活动产生的现金流量净额 | 7,431,738.82 | 8,004,168.78 | 21,018,389.56 | 15,179,779.24 |
| 汇率变动对现金及现金等价物的影响 | -359,596.12 | -241,730.26 | -182,486.94 | -103,782.15 |
| 现金及现金等价物净增加额 | -14,843,217.01 | -16,381,033.16 | 56,118,912.39 | 36,950,834.68 |
| 期末现金及现金等价物余额 | 145,759,495.49 | 144,221,679.34 | 160,602,712.5 | 141,434,634.79 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -14,843,217.01 | - | 56,118,912.39 | - |